Disc Medicine Stock Plunges As Light Sensitivity Treatment Data Confounded Due To Outsized Placebo Response
Portfolio Pulse from Vandana Singh
Disc Medicine Inc (NASDAQ:DISC) reported Phase 2 study results for bitopertin in Erythropoietic Protoporphyria (EPP), showing significant reductions in PPIX levels and improvements in phototoxic reactions. However, the placebo group's strong performance led to non-significant results in some secondary endpoints. DISC stock plunged 58.57% to $25.80.
April 01, 2024 | 2:52 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Disc Medicine Inc reported promising Phase 2 results for bitopertin in EPP treatment, but faced a significant stock price drop due to the strong placebo response.
The significant drop in DISC's stock price is directly related to the market's reaction to the mixed results from the Phase 2 study of bitopertin. While the treatment showed significant efficacy in primary endpoints, the strong performance of the placebo group in secondary endpoints likely raised concerns among investors about the drug's market potential and regulatory approval prospects.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100